Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics
AbstractWhile translational regulation of p53 by the internal ribosome entry site (IRES) at its 5′-untranslated region following DNA damage has been widely accepted, the detailed mechanism underlying the translational control of p53 by its IRES sequence is still poorly understood. In this review, we will focus on the latest progress in identifying novel regulatory proteins of the p53 IRES and in uncovering the functional connection between defective IRES-mediated p53 translation and tumorigenesis. We will also discuss how these findings may lead to a better understanding of the process of oncogenesis and open up new avenues for cancer diagnosis and therapeutics. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Ji, B.; Harris, B.R.E.; Liu, Y.; Deng, Y.; Gradilone, S.A.; Cleary, M.P.; Liu, J.; Yang, D.-Q. Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics. Int. J. Mol. Sci. 2017, 18, 93.
Ji B, Harris BRE, Liu Y, Deng Y, Gradilone SA, Cleary MP, Liu J, Yang D-Q. Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics. International Journal of Molecular Sciences. 2017; 18(1):93.Chicago/Turabian Style
Ji, Bai; Harris, Benjamin R.E.; Liu, Yahui; Deng, Yibin; Gradilone, Sergio A.; Cleary, Margot P.; Liu, Jianhua; Yang, Da-Qing. 2017. "Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics." Int. J. Mol. Sci. 18, no. 1: 93.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.